预约演示
更新于：2025-04-16
Dapoxetine Hydrochloride
盐酸达泊西汀
更新于：2025-04-16
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 英国 (2008-12-17), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H24ClNO |
InChIKeyIHWDIQRWYNMKFM-BDQAORGHSA-N |
CAS号129938-20-1 |
关联
109
项与 盐酸达泊西汀 相关的临床试验CTR20250171
盐酸达泊西汀片在中国成年健康男性受试者中的一项单中心、随机、开放、空腹和餐后单次给药、两制剂、两序列、两周期交叉的生物等效性研究
CTR20250263
山东济坤生物制药有限公司研制的盐酸达泊西汀片与参比制剂在中国健康受试者中进行的单中心、随机、开放、两制剂、空腹和餐后、单次给药、两周期、双交叉设计的生物等效性研究
CTR20244447
盐酸达泊西汀片人体生物等效性试验
100 项与 盐酸达泊西汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸达泊西汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸达泊西汀 相关的专利（医药）
登录后查看更多信息
409
项与 盐酸达泊西汀 相关的文献（医药）2025-04-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Identification of Phosphodiesterase type 5 inhibitors (PDE5is) analogues using surface-enhanced Raman scattering and machine learning algorithm
Article
作者: Huang, Jiadong ; He, Hongyuan ; Li, Yujing ; Luan, Yujing
Phosphodiesterase type 5 inhibitors (PDE5is), primarily used for the treatment of erectile dysfunction, have been severely misused in recent years, posing a threat to public health and safety. This study developed a method that combines Surface-enhanced Raman spectroscopy (SERS) with machine learning algorithms to rapidly identify different PDE5is types. A total of 948 SERS spectra from 79 PDE5is were collected using gold nanoparticles (AuNPs) as the enhancement agent, and dimensionality reduction was performed through principal component analysis (PCA). Subsequently, six traditional machine learning models, partial least squares discriminant analysis (PLS-DA), orthogonal partial least squares discriminant analysis (OPLS-DA), support vector machines (SVM), k-nearest neighbors (KNN), random forest (RF), and multilayer perceptron (MLP) were applied for data classification and identification. Results showed that the MLP model achieved the highest classification accuracy of 99.65 %, with only 1.82 % of the samples misclassified from thiosildenafil to sildenafil analogues, significantly outperforming the other models. This method offers a rapid, cost-effective, and accurate alternative for the detection of PDE5is in health foods, with implications for improving regulatory oversight and public health safety.
2025-03-07ORGANIC LETTERS
Manganese(I)-Catalyzed Enantioselective Formal Anti-Markovnikov Hydroalkoxylation of Racemic Allylic Alcohols: A Borrowing Hydrogen Access
Article
作者: Fan, Qing-Hua ; Li, Faju ; Liu, Shuai-Hu ; He, Yan-Mei
An enantioselective manganese(I)-catalyzed formal anti-Markovnikov hydroalkoxylation of racemic allylic alcohols has been developed using a chiral N6-type macrocyclic ligand, affording a wide range of chiral γ-alkoxypropyl alcohols in high isolated yields with excellent enantioselectivities. The synthetic utility of this protocol was further proven by gram-scale synthesis of chiral γ-alkoxypropanol 3n and derivatization of chiral γ-alkoxypropanol 3a to a drug molecule, (S)-dapoxetine, for the treatment of premature ejaculation and erectile dysfunction. Mechanistic studies support that the reaction proceeds via a hydrogen-borrowing cascade reaction pathway.
2025-03-01Chem
Excited-state protonation and reduction enable the umpolung Birch reduction of naphthalenes
作者: Corpas, Javier ; Rivera-Chao, Eva ; Katayama, Yuri ; de la Pena O′Shea, Victor A. ; Bouchel, Celine ; Leonori, Daniele ; Arpa, Enrique M. ; Jacob, Clement ; Ruffoni, Alessandro ; Gomez-Mendoza, Miguel ; Echeverria, Pierre-Georges
The Birch reaction is a classical process used for the partial reduction of aromatics into non-conjugated cyclohexadienes that can be further functionalized.This strategy and its more modern variants are all based on an initial single-electron transfer event converting the arene into the corresponding radical anion for either protonation or hydrogen-atom transfer.Herein, we demonstrate an umpolung approach where the aromatic is first protonated to its corresponding carbocation and then reduced using the Lewis acid-base complex Et3N-BH3.This strategy requires aromatic photoexcitation so that protonation is favored by charge-transfer and driven by excited-state antiaromaticity relief.This means that aromatic excited-state basicity rather than ground-state redox potential needs to be considered when approaching reaction development.The mild conditions and the avoidance of strong reductants have enabled tolerance of functionalities generally not compatible under standard Birch conditions.
100 项与 盐酸达泊西汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 早泄 | 奥地利 | 2008-12-17 | |
| 早泄 | 比利时 | 2008-12-17 | |
| 早泄 | 保加利亚 | 2008-12-17 | |
| 早泄 | 克罗地亚 | 2008-12-17 | |
| 早泄 | 塞浦路斯 | 2008-12-17 | |
| 早泄 | 捷克 | 2008-12-17 | |
| 早泄 | 爱沙尼亚 | 2008-12-17 | |
| 早泄 | 芬兰 | 2008-12-17 | |
| 早泄 | 法国 | 2008-12-17 | |
| 早泄 | 德国 | 2008-12-17 | |
| 早泄 | 希腊 | 2008-12-17 | |
| 早泄 | 匈牙利 | 2008-12-17 | |
| 早泄 | 爱尔兰 | 2008-12-17 | |
| 早泄 | 意大利 | 2008-12-17 | |
| 早泄 | 立陶宛 | 2008-12-17 | |
| 早泄 | 卢森堡 | 2008-12-17 | |
| 早泄 | 马耳他 | 2008-12-17 | |
| 早泄 | 荷兰 | 2008-12-17 | |
| 早泄 | 波兰 | 2008-12-17 | |
| 早泄 | 葡萄牙 | 2008-12-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 勃起功能障碍 | 临床3期 | 美国 | 2010-04-01 | |
| 勃起功能障碍 | 临床3期 | 阿根廷 | 2010-04-01 | |
| 勃起功能障碍 | 临床3期 | 澳大利亚 | 2010-04-01 | |
| 勃起功能障碍 | 临床3期 | 比利时 | 2010-04-01 | |
| 勃起功能障碍 | 临床3期 | 加拿大 | 2010-04-01 | |
| 勃起功能障碍 | 临床3期 | 法国 | 2010-04-01 | |
| 勃起功能障碍 | 临床3期 | 马来西亚 | 2010-04-01 | |
| 勃起功能障碍 | 临床3期 | 墨西哥 | 2010-04-01 | |
| 勃起功能障碍 | 临床3期 | 波兰 | 2010-04-01 | |
| 勃起功能障碍 | 临床3期 | 俄罗斯 | 2010-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 鏇蓋簾鏇鹽製範鹹襯簾(製窪積製繭獵積鑰鹽糧) = 齋壓範築夢鏇襯積積顧 網選壓獵窪蓋夢蓋鏇淵 (鏇夢餘齋鏇艱憲襯簾選, 23.0 ~ 400.0) | 积极 | 2024-05-01 | |||
OLNP-05 | 鏇蓋簾鏇鹽製範鹹襯簾(製窪積製繭獵積鑰鹽糧) = 網簾製簾襯衊鬱選壓鹹 網選壓獵窪蓋夢蓋鏇淵 (鏇夢餘齋鏇艱憲襯簾選, 140.0 ~ 410.0) | ||||||
临床3期 | 495 | Placebo | 構鹹膚顧糧選鬱構壓齋(顧網獵憲艱窪衊鏇憲淵) = Incidence of TEAEs was 20.0% and 29.6% in placebo- and dapoxetine-treated subjects, respectively (P = 0.0135) 醖鹽積積鬱蓋鏇範衊獵 (鑰鹽蓋選範觸憲鹽夢憲 ) 更多 | 积极 | 2013-09-01 | ||
临床3期 | 495 | Placebo (PDE5I + Placebo (Baseline)) | 鏇構繭夢獵鑰襯獵壓窪(窪壓願憲鏇範網遞衊網) = 築積窪醖齋選遞淵夢憲 遞膚選夢願餘構齋積壓 (遞艱遞網鹽齋鹹夢衊壓, 0.53) | - | 2012-11-04 | ||
Placebo (PDE5I + Placebo (Week 12)) | 鏇構繭夢獵鑰襯獵壓窪(窪壓願憲鏇範網遞衊網) = 鹽鹽艱鏇廠衊鏇餘齋顧 遞膚選夢願餘構齋積壓 (遞艱遞網鹽齋鹹夢衊壓, 3.54) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用